Viral Specific T-cells for Treatment of COVID-19

Withdrawn before enrolling · Phase 2

Conditions studied: Viral Infection

In brief

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) when given in the presence of COVID-19 signs and symptoms, caused by the virus SARS-CoV-2. VSTs are cells specially designed to fight viral infections. These cells are created from a blood sample collected from a donor who has recovered from COVID-19 infection. VSTs are investigational meaning that they are not approved by the Food and Drug Administration (FDA). COVID-19 is a new virus and treatment options are evolving rapidly. VSTs have been successfully used to treat many different viral infections and may be beneficial in treating COVID-19 in the absence of other treatments.

Key facts

Study ID
NCT04406064
Run by
Children's Hospital Medical Center, Cincinnati
People needed
0
Starts
2021-01-01
Expected to finish
2025-06-01
Last updated by the study team
2021-01-19

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.